Douglas M. Smith
United States of America
Dr. Smith joined NanoBio Corporation in November 2013 with over 20 years of experience in immunology, including cellular and antibody-based immunotherapies and vaccines against cancer and infectious diseases. He received a B.Sc. degree in microbiology and immunology from McGill University and a Ph.D. in immunology from the University of Chicago. As Principal Scientist and Immunology Program Leader at Aastrom Biosciences, Inc., he established and directed programs for clinical-scale production of dendritic cell vaccines, T-lymphocyte-based adoptive immunotherapies, and immunologic characterization of an adult stem cell product for human tissue repair. Dr. Smith gained extensive experience in the development, characterization, and evaluation of nanoemulsions as novel adjuvants for induction of mucosal and systemic immunity as a faculty member of the Michigan Nanotechnology Institute for Medicine and Biological Sciences (2008-2013) at the University of Michigan. He is currently responsible for development of NanoVax-PanFlu, a nanoemulsion-adjuvanted vaccine against H5N1 pandemic influenza, and other mucosal vaccines to prevent respiratory or sexually-transmitted diseases such as herpes simplex virus and HIV/AIDS.
Immunology, including Cellular and Antibody-based Immunotherapies and Vaccines against cancer and infectious diseases